Perlin Cássio Marques, Ferreira Vinicius Lins, Borba Helena Hiemisch Lobo, Wiens Astrid, Ivantes Cláudia Alexandra Pontes, Lenzi Luana, Pontarolo Roberto
Universidade Federal do Paraná, Programa de Pós-Graduação em Assistência Farmacêutica, Curitiba, Paraná, Brazil.
Universidade Federal do Paraná, Programa de Pós-Graduação em Ciências Farmacêuticas, Curitiba, Paraná, Brazil.
Rev Inst Med Trop Sao Paulo. 2017 Dec 21;59:e81. doi: 10.1590/S1678-9946201759081.
Multiple factors negatively affect the quality of life of patients infected with hepatitis C virus. This study aims to evaluate the effect of pharmacological treatment on the quality of life of these individuals.
This is a cross-sectional study conducted in two Southern Brazilian centers that used two instruments (a generic and a specific one) for measuring the quality of life in patients with chronic hepatitis C: the Short Form-36 (SF-36); and the Chronic Liver Disease Questionnaire (CLDQ) for liver disease. We included patients from two centers without any treatment (control group), or receiving medication (peginterferon + ribavirin ± telaprevir or boceprevir, i.e., respectively, dual, and triple therapies).
One hundred and forty-seven patients were included. Patients under treatment (n = 86) had a lower score in 7 of the 8 SF-36 domains, with statistical significance (p<0.05) only for the emotional function domain. Patients who were not treated (n = 58) had higher scores in 4 of the 6 (p<0.05) CLDQ domains. A comparison of patients, receiving dual or triple therapies for both questionnaires, was only significant in the Vitality domain from CLDQ.
Treatment can affect the subjective perception of patients regarding quality of life. Due to the complexity of the disease, each patient must be evaluated in multiple dimensions. Thus, the results may be useful for understanding the patient's perceptions during treatment, and it can also serve as a reference for care instructions.
多种因素对丙型肝炎病毒感染患者的生活质量产生负面影响。本研究旨在评估药物治疗对这些个体生活质量的影响。
这是一项在巴西南部两个中心开展的横断面研究，该研究使用两种工具（一种通用工具和一种特定工具）来测量慢性丙型肝炎患者的生活质量：简短健康调查问卷（SF-36）；以及用于肝病的慢性肝病问卷（CLDQ）。我们纳入了来自两个中心未接受任何治疗的患者（对照组），或正在接受药物治疗的患者（聚乙二醇干扰素+利巴韦林±特拉匹韦或博赛泼维，即分别为双重和三重疗法）。
共纳入147例患者。接受治疗的患者（n = 86）在SF-36的8个领域中的7个领域得分较低，仅情感功能领域具有统计学意义（p<0.05）。未接受治疗的患者（n = 58）在CLDQ的6个领域中的4个领域得分较高（p<0.05）。对于两份问卷，接受双重或三重疗法的患者之间的比较仅在CLDQ的活力领域具有显著性。
治疗可影响患者对生活质量的主观感受。由于疾病的复杂性，必须对每位患者进行多维度评估。因此，这些结果可能有助于了解治疗期间患者的感受，也可为护理指导提供参考。
